Cardiff Oncology Reports Third Quarter 2022 Results and Provides Business Updates
/PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a...
Source: prnewswire.com